查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602820

抗凝血剂市场：按给药途径、抗凝血剂、药物类别和应用划分 - 2025-2030 年全球预测

Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

据预测，2023年抗凝血药物市值为402亿美元，预计2024年将达到442.4亿美元，复合年增长率为10.14%，到2030年将达到790.7亿美元。

抗凝血剂是一类预防血栓形成的药物，血栓形成可能导致中风、心臟病和深层静脉栓塞症等疾病。抗凝血剂在血栓性疾病的管理和预防中至关重要，因此涵盖製药、生物技术和医疗领域。心血管疾病盛行率不断上升，以及更容易患此类疾病的老年人数量不断增加，推动了对这些药物的需求。抗凝血剂的应用遍及医院、诊所和居家医疗，用于治疗和预防方案。最终用途范围主要涉及医疗保健提供者，研究机构和药品製造商是开发和分销的主要相关人员。关键的成长要素包括药物输送系统的进步、对血栓症形成认识的提高以及采用新型口服药物（NOAC）来取代Warfarin等传统治疗方法。该市场也受到亚太地区新兴市场和特异性抗凝血剂等技术创新的推动，提供了利润丰厚的机会。

主要市场统计
基准年[2023] 402亿美元
预测年份 [2024] 442.4亿美元
预测年份 [2030] 790.7亿美元
复合年增长率（%） 10.14%

然而，市场成长面临挑战，例如 NOAC 的高成本、严格的法规结构以及需要仔细病患监测的出血併发症的风险。解毒剂的开发仍然是一个重大限制，影响了 NOAC 的广泛使用。技术创新和研究正在进行中，以开发更安全、更有效、副作用更少的药物。利用药物基因学见解进行个人化药物治疗是业务成长的一个有希望的前沿领域。市场竞争激烈，主要企业在研发方面投入大量资金。因此，利用现实世界的资料和人工智慧来改善患者的治疗结果为未来的探索提供了一个令人兴奋的领域，并最终完善抗凝血剂的治疗指标，我们的目标是减少这些问题。

市场动态：揭示快速发展的抗凝血剂市场的关键市场洞察

供需的动态交互作用正在改变抗凝血剂市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 静脉血栓栓塞症和心血管疾病的盛行率增加
    • 增加抗凝血管理计划
    • 扩大新型口服抗凝血剂的接受度
  • 市场限制因素
    • 关于剂量和临床核准的严格规定
  • 市场机会
    • 采用新的抗凝血治疗方法并增加研发投入
    • 利用人工智慧和机器学习预测抗凝血控制
  • 市场问题
    • 与使用口服药物相关的副作用和併发症

波特五力：驾驭抗凝血药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解抗凝血剂市场的外部影响

外部宏观环境因素在塑造抗凝血剂市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解抗凝血剂市场的竞争格局

抗凝血剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：抗凝血剂市场供应商绩效评估

FPNV定位矩阵是评估抗凝血剂市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划抗凝血市场的成功之路

抗凝血剂市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 静脉血栓栓塞症和心血管疾病的发生率增加
      • 增加抗凝血治疗管理计划
      • 关于抗凝血剂的新口头陈述的接受度提高
    • 抑制因素
      • 严格的药物剂量和临床核准规定
    • 机会
      • 采用新的抗凝血疗法并增加研发投入
      • 使用人工智慧和机器学习预测抗凝血控制
    • 任务
      • 与口服抗凝血剂相关的副作用和併发症
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 抗凝血药物市场：依给药途径分类

  • 介绍
  • 注射抗凝血剂
  • 口服抗凝血剂

第七章 抗凝血剂市场：依抗凝血剂分类

  • 介绍
  • 贝曲西班
  • Dabigatran
  • 艾多沙班或利伐沙班
  • 埃利奎斯

第八章抗凝血剂市场：依药物类别

  • 介绍
  • DTIs
  • XA因子抑制剂
  • 肝素
  • 维生素K拮抗剂

第九章抗凝血剂市场：依应用分类

  • 介绍
  • 心房颤动和心臟病发作
  • 深层静脉栓塞症
  • 肺动脉栓塞
  • 中风

第10章美洲抗凝血药市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太抗凝血市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲抗凝血市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Akebia Therapeutics, Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Athenex, Inc.
  • Bayer AG
  • CH Boehringer Sohn AG & Ko. KG
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • LEO Pharma A/S
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4358BACA80B8

The Anticoagulants Market was valued at USD 40.20 billion in 2023, expected to reach USD 44.24 billion in 2024, and is projected to grow at a CAGR of 10.14%, to USD 79.07 billion by 2030.

Anticoagulants are a class of drugs that prevent blood clot formation, which could lead to conditions such as stroke, heart attack, and deep vein thrombosis. The scope of anticoagulants spans across pharmaceuticals, biotechnology, and healthcare sectors as they are crucial in managing and preventing thrombotic disorders. The necessity of these drugs arises due to the increasing prevalence of cardiovascular diseases and the growing geriatric population, who are more prone to such conditions. The application of anticoagulants extends to hospitals, clinics, and homecare settings, where they are used in both therapeutic and preventive regimens. The end-use scope predominantly involves healthcare providers, whereas research institutions and pharmaceutical manufacturers are crucial stakeholders in the development and distribution. Key growth factors include advancements in drug delivery systems, increasing awareness about thrombotic conditions, and the adoption of novel oral anticoagulants (NOACs) which offer an alternative to traditional therapies like warfarin. This market also presents lucrative opportunities, propelled by emerging markets in Asia-Pacific and technological innovations like target-specific anticoagulants.

KEY MARKET STATISTICS
Base Year [2023] USD 40.20 billion
Estimated Year [2024] USD 44.24 billion
Forecast Year [2030] USD 79.07 billion
CAGR (%) 10.14%

However, market growth faces challenges like the high cost of NOACs, stringent regulatory frameworks, and the risk of bleeding complications, which necessitate careful patient monitoring. The development of antidotes remains a critical limitation, affecting the widespread adoption of NOACs. Innovation and research are being directed toward the creation of safer and more effective anticoagulants with fewer side effects. Personalization of drug therapy using pharmacogenetic insights represents a promising frontier for business growth. The nature of the market is increasingly competitive, with significant investments in R&D from leading pharmaceutical companies. Consequently, the use of real-world data and artificial intelligence to improve patient outcomes presents an exciting area for future exploration, ultimately aiming to refine the therapeutic index of anticoagulants and mitigate their challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticoagulants Market

The Anticoagulants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of venous thromboembolism and cardiovascular disorders
    • Rising number of anticoagulation stewardship programs
    • Increasing acceptance of novel oral anticoagulants
  • Market Restraints
    • Stringent regulations related to drug dosage and clinical approvals
  • Market Opportunities
    • Introduction of novel anticoagulation therapeutics and increasing R&D investments
    • Use of AI and ML to predict anticoagulation control
  • Market Challenges
    • Side-effects and complications associated with the usage of oral anticoagulants

Porter's Five Forces: A Strategic Tool for Navigating the Anticoagulants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticoagulants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticoagulants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticoagulants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticoagulants Market

A detailed market share analysis in the Anticoagulants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticoagulants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticoagulants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticoagulants Market

A strategic analysis of the Anticoagulants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulants Market, highlighting leading vendors and their innovative profiles. These include Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Injectable Anticoagulants and Oral Anticoagulants.
  • Based on Anticoagulant Drug, market is studied across Betrixaban, Dabigatran, Edoxaban or Rivaroxaban, and Eliquis.
  • Based on Drug Class, market is studied across DTIs, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists.
  • Based on Application, market is studied across Atrial fibrillation & Heart Attack, Deep Vein Thrombosis, Pulmonary Embolism, and Stroke.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
      • 5.1.1.2. Rising number of anticoagulation stewardship programs
      • 5.1.1.3. Increasing acceptance of novel oral anticoagulants
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
      • 5.1.3.2. Use of AI and ML to predict anticoagulation control
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects and complications associated with the usage of oral anticoagulants
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anticoagulants Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Injectable Anticoagulants
  • 6.3. Oral Anticoagulants

7. Anticoagulants Market, by Anticoagulant Drug

  • 7.1. Introduction
  • 7.2. Betrixaban
  • 7.3. Dabigatran
  • 7.4. Edoxaban or Rivaroxaban
  • 7.5. Eliquis

8. Anticoagulants Market, by Drug Class

  • 8.1. Introduction
  • 8.2. DTIs
  • 8.3. Factor XA Inhibitors
  • 8.4. Heparin
  • 8.5. Vitamin K Antagonists

9. Anticoagulants Market, by Application

  • 9.1. Introduction
  • 9.2. Atrial fibrillation & Heart Attack
  • 9.3. Deep Vein Thrombosis
  • 9.4. Pulmonary Embolism
  • 9.5. Stroke

10. Americas Anticoagulants Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anticoagulants Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anticoagulants Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akebia Therapeutics, Inc.
  • 2. Aspen Pharmacare Holdings Limited
  • 3. AstraZeneca PLC
  • 4. Athenex, Inc.
  • 5. Bayer AG
  • 6. C.H. Boehringer Sohn AG & Ko. KG
  • 7. Eisai Co., Ltd.
  • 8. Eli Lilly and Company
  • 9. Johnson & Johnson
  • 10. LEO Pharma A/S
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. ANTICOAGULANTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICOAGULANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTICOAGULANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICOAGULANTS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY BETRIXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY EDOXABAN OR RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ELIQUIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTICOAGULANTS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION & HEART ATTACK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTICOAGULANTS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023